| Literature DB >> 35447934 |
Tse-Hung Huang1,2,3,4,5, Chiao-Hsu Ke6, Chin-Chang Chen7, Cheng-Hsun Chuang8,9, Kuang-Wen Liao8,9,10,11, Yi-Hsien Shiao1, Chen-Si Lin6.
Abstract
Freshwater clam extract (FCE) is a functional food that regulates the immune system and has been demonstrated in numerous studies to display desirable anti-tumor necrosis factor-alpha (TNF-α) responses. In addition, excess TNF-α production is positively associated with type 2 diabetes. However, few longitudinal clinical studies evaluating the efficiency and toxicity of FCE are available. This article reports that patients with prediabetes who received FCE had a desirable outcome of a reduction in serum TNF-α for a long period. This was a double-blind, randomized, parallel clinical trial conducted using FCE intervention and placebo groups, and 36 patients with prediabetes were enrolled. Two grams of FCE or placebo was consumed daily for 180 consecutive days. The serum of the participants was collected at four time points (0M: before the intervention; 3M: after 3 months of intervention; 6M: after 6 months of intervention; 12M: 6 months after cessation of intervention at 6M). A serum TNF-α concentration higher than 4.05 pg/mL was defined as a cut-off value. FCE reduced serum TNF-α in all participants at 6M and 12M. Moreover, FCE significantly suppressed serum TNF-α concentrations at 6M and 12M and inhibited TNF-α release with time series in subjects with elevated TNF-α values. FCE intervention effectively reduced serum TNF-α and persistently sustained the effects for half a year in patients with prediabetes. Gas chromatography-mass spectrometry (GS-MS) analysis revealed that the major components of FCE were phytosterols and fatty acids, which exerted anti-inflammatory and anti-TNF-α abilities. Hence, FCE has the potential to be developed as a natural treatment for prediabetic patients in Taiwan.Entities:
Keywords: Corbicula fluminea; freshwater clam extract; prediabetes; tumor necrosis factor-alpha
Mesh:
Substances:
Year: 2022 PMID: 35447934 PMCID: PMC9027770 DOI: 10.3390/md20040261
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085